SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-004274
Filing Date
2023-01-09
Accepted
2023-01-09 09:26:03
Documents
15
Period of Report
2023-01-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d446015d8k.htm   iXBRL 8-K 25666
2 EX-99.1 d446015dex991.htm EX-99.1 35730
6 GRAPHIC g446015dsp7a.jpg GRAPHIC 6297
7 GRAPHIC g446015dsp7b.jpg GRAPHIC 2081
  Complete submission text file 0001193125-23-004274.txt   202273

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rprx-20230109.xsd EX-101.SCH 2855
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rprx-20230109_lab.xml EX-101.LAB 17234
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rprx-20230109_pre.xml EX-101.PRE 10815
9 EXTRACTED XBRL INSTANCE DOCUMENT d446015d8k_htm.xml XML 3298
Mailing Address 110 EAST 59TH STREET NEW YORK NY 10022
Business Address 110 EAST 59TH STREET NEW YORK NY 10022 (212) 883-0200
Royalty Pharma plc (Filer) CIK: 0001802768 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39329 | Film No.: 23516882
SIC: 2834 Pharmaceutical Preparations